Résumé :
|
[BDSP. Notice produite par INIST R0xI7aTC. Diffusion soumise à autorisation]. Context Although the cost-effectiveness and cost-benefit of influenza vaccination are well established for persons aged 65 years or older, the benefits for healthy adults younger than 65 years are less clear. Objective To evaluate the effectiveness and cost-benefit of influenza vaccine in preventing influenzalike illness (ILI) and reducing societal costs of ILI among healthy working adults. Design Double-blind, randomized, placebo-controlled trial conducted during 2 influenza seasons. Setting and Participants Healthy adults aged 18 to 64 years and employed full-time by a US manufacturing company (for 1997-1998 season, n=1184 ; for 1998-1999 season, n=1191). Interventions For each season, participants were randomly assigned to receive either trivalent inactivated influenza vaccine (n=595 in 1997-1998 and n=587 in 1998-1999) or sterile saline injection (placebo ; n=589 in 1997-1998 and n=604 in 1998-1999). Participants in 1997-1998 were rerandomized if they participated in 1998-1999. Main Outcome Measures Influenzalike illnesses and associated physician visits and work absenteeism reported in biweekly questionnaires by all participants, and serologically confirmed influenza illness among 23% of participants in each year (n=275 in 1997-1998 ; n=278 in 1998-1999) ; societal cost of ILI per vaccinated vs unvaccinated person. (...)
|